HYPOMETHYLATING AGENT THERAPY USE AND SURVIVAL IN OLDER PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROMES IN USA: A LARGE POPULATION-BASED STUDY

被引：0

作者：

Zeidan, A. ^{[1
]}

Hu, X. ^{[1
]}

Long, J. B. ^{[1
]}

Wang, R. ^{[2
]}

Huntington, S. F. ^{[1
]}

Podoltsev, N. ^{[1
]}

Giri, S. ^{[1
]}

Stahl, M. ^{[1
]}

Gore, S. ^{[1
]}

Ma, X. ^{[2
]}

Davidoff, A. J. ^{[3
]}

机构：

[1] Yale Univ, Dept Med, New Haven, CT 06520 USA

[2] Yale Univ, Yale Sch Publ Hlth, Epidemiol, New Haven, CT USA

[3] Yale Univ, Yale Sch Publ Hlth, Hlth Policy & Management, New Haven, CT USA

来源：

LEUKEMIA RESEARCH | 2017年 / 55卷

关键词：

D O I：

10.1016/S0145-2126(17)30234-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

121

引用

页码：S75 / S76

页数：2

共 50 条

[1] Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.
Zeidan, Amer M.
Hu, Xin
Long, Jessica B.
Wang, Rong
Huntington, Scott F.
Podoltsev, Nikolai Alexandrovich
Giri, Smith
Stahl, Maximilian
Gore, Steven
Ma, Xiaomei
Davidoff, Amy J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[2] HYPOMETHYLATING AGENT THERAPY USE AND SURVIVAL IN OLDER PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA IN USA: A LARGE POPULATION-BASED STUDY
Zeidan, A.
Hu, X.
Long, J. B.
Wang, R.
Ma, X.
Podoltsev, N.
Huntington, S.
Gore, S. D.
Davidoff, A. J.
[J]. LEUKEMIA RESEARCH, 2017, 55 : S20 - S21
[3] Long-Term Survival of Older Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agent Therapy: A Large Population-Based Analysis
Stahl, Maximilian
Hu, Xin
Wang, Rong
Ma, Xiaomei
Huntington, Scott
Podoltsev, Nikolai A.
Gore, Steven D.
Abel, Gregory A.
Davidoff, Amy J.
Zeidan, Amer M.
[J]. BLOOD, 2017, 130
[4] Hypomethylating Agent Therapy Use and Survival in Older Patients With Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study
Zeidan, Amer M.
Hu, Xin
Long, Jessica B.
Wang, Rong
Ma, Xiaomei
Podoltsev, Nikolai A.
Huntington, Scott F.
Gore, Steven D.
Davidoff, Amy J.
[J]. CANCER, 2017, 123 (19) : 3754 - 3762
[5] Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study
Zeidan, Amer M.
Hu, Xin
Long, Jessica B.
Wang, Rong
Huntington, Scott F.
Podoltsev, Nikolai A.
Gore, Steven
Ma, Xiaomei
Davidoff, Amy J.
[J]. BLOOD, 2016, 128 (22)
[6] Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis
Zeidan, Amer M.
Hu, Xin
Zhu, Weiwei
Stahl, Maximilian
Giri, Smith
Huntington, Scott F.
Wang, Rong
Podoltsev, Nikolai A.
Gore, Steven D.
Ma, Xiaomei
Davidoff, Amy J.
[J]. BLOOD, 2018, 132
[7] Under-use of Hypomethylating Agents in Patients With Higher-risk Myelodysplastic Syndrome in the United States: A Large Population-based Analysis
Corman, Shelby
Joshi, Namita
Wert, Tim
Kale, Hrishikesh
Hill, Kala
Zeidan, Amer M.
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (02): : E206 - E211
[8] Treatment Utilization and Characteristics Among Patients with Higher-Risk Myelodysplastic Syndromes According to Hypomethylating Agent Use
Zeidan, Amer M.
Divino, Victoria
DeKoven, Mitch
Shah, Drishti
Wang, Elizabeth
Bey, Dawn
Salimi, Tehseen
Epstein, Robert S.
[J]. BLOOD, 2021, 138
[9] HOSPITALIZATION AND EMERGENCY ROOM VISITS AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES BY HYPOMETHYLATING AGENT USE
Zeidan, A. M.
Joshi, N.
Kale, H.
Wang, W. -J.
Corman, S.
Hill, K.
Salimi, T.
Epstein, R.
[J]. LEUKEMIA RESEARCH, 2021, 108 : S26 - S26
[10] Practical Recommendations for Hypomethylating Agent Therapy of Patients With Myelodysplastic Syndromes
Steensma, David P.
Stone, Richard M.
[J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 24 (02) : 389 - +

← 1 2 3 4 5 →